STOCK TITAN

Cocrystal (COCP) director Brosgart files with zero reported holdings

(Neutral)
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Cocrystal Pharma, Inc. (ticker COCP) reports that Carol L. Brosgart is a director of the company in this initial statement of beneficial ownership on Form 3. The filing does not list any reportable holdings or transactions and includes an exhibit identified as a Power of Attorney.

Positive

  • None.

Negative

  • None.
Form 3 regulatory
"this initial statement of beneficial ownership on Form 3"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Power of Attorney regulatory
"Exhibit 24 - Power of Attorney"
A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.
beneficial ownership financial
"initial statement of beneficial ownership on Form 3"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

What does this Form 3 filing disclose for COCP?

It discloses that Carol L. Brosgart is a director of Cocrystal Pharma, Inc. and files an initial statement of beneficial ownership on Form 3. The filing shows no reportable transactions or holdings and notes an accompanying Power of Attorney as an exhibit.

Did Carol L. Brosgart report any COCP share transactions in this Form 3?

No. The Form 3 for Cocrystal Pharma, Inc. shows no reported transactions, with all buy, sell, acquire, dispose, and other transaction counts listed as zero in the transaction summary.

Is Carol L. Brosgart reported as a 10% owner of COCP in this filing?

No. The reporting person section states that Carol L. Brosgart is a director of Cocrystal Pharma, Inc. and is not indicated as a ten percent owner in this Form 3.

Does the COCP Form 3 indicate any derivative securities for Carol L. Brosgart?

No. The derivativeSummary is empty and the transaction summary shows zero derivative transactions, so no options, warrants, or other derivative positions are reported in this Form 3.

What additional document is referenced in this COCP Form 3?

The remarks section references Exhibit 24 - Power of Attorney, indicating that a power of attorney document is associated with this Form 3 filing for Cocrystal Pharma, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Brosgart Carol L

(Last)(First)(Middle)
19805 N. CREEK PARKWAY

(Street)
BOTHELL WASHINGTON 98011

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
08/12/2026
3. Issuer Name and Ticker or Trading Symbol
Cocrystal Pharma, Inc. [ COCP ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
Remarks:
Exhibit 24 - Power of Attorney
No securities are beneficially owned.
/s/ Carol L Brosgart08/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)